natgillin/translations-raw huggingface dataset:
Antitrombocyt-effekten kan teoretisk blive ændret og bør overvåges nøje, når cilostazol administreres sammen med CYP3A4- og CYP2C19-inducere.
The antiplatelet effect may theoretically be altered and should be carefully monitored when cilostazol is co-administered with CYP3A4 and CYP2C19 inducers.
Cilostazol skal straks seponeres, hvis der er kliniske eller laboratoriemæssige tegn på hæmatologisk unormale forhold.
Cilostazol should be discontinued promptly if there is clinical or laboratory evidence of haematological abnormalities.
Baseret på dets virkemekanisme kan cilostazol inducere takykardi, palpitationer, takyarytmi og/eller hypotension.
Based on its mechanism of action, cilostazol may induce tachycardia, palpitation, tachyarrhythmia and/or hypotension.
Din læge kan dog ordinere en lavere dosis, hvis du får andre lægemidler, der kan påvirke virkningen af <lægemidler indeholdende cilostazol>.
However, your doctor may prescribe a lower dose if you are taking other medicines which may have an effect on <Cilostazol-containing medicinal product>.
Maven skal tømmes ved at fremkalde opkastning eller ved maveudskylning, alt efter hvad der er relevant.
The stomach should be emptied by induced vomiting or gastric lavage, as appropriate.
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) Til peroral anvendelse
METHOD AND ROUTE(S) OF ADMINISTRATION
Cilostazol i sig selv kan medføre en øget blødningsrisiko, og denne risiko kan blive forstærket ved samtidig administration af andre midler med et sådant potentiale.
Cilostazol per se may carry an increased risk of bleeding and this risk may be potentiated by coadministration with any other agent with such potential.
Der findes ingen data for patienter med moderat til svær leverinsufficiens, og da cilostazol metaboliseres i høj grad af leverenzymer, bør medicinen ikke anvendes til sådanne patienter (se pkt.
There are no data in patients with moderate to severe hepatic impairment and since cilostazol is extensively metabolised by hepatic enzymes, the medicine must not be used in such patients (see section 4.3).
Før du begynder at tage <lægemidlet indeholdende cilostazol>, skal du fortælle din læge det, hvis du tager medicin for højt blodtryk, idet lægemidlet indeholdende cilostazol kan sænke dit blodtryk yderligere.
Before you start taking <Cilostazol-containing medicinal product>, please inform your doctor if you are taking medicines for high blood pressure because <Cilostazol-containing medicinal product> may have an additional lowering effect on your blood pressure.
Hvis du af en eller anden grund har taget flere tabletter indeholdende cilostazol end du skulle, kan du opleve tegn og symptomer som svær hovedpine, diare, et fald i blodtrykket og uregelmæssige hjerteslag.
If you take more <Cilostazol-containing medicinal product> than you should If for any reason you have taken more <Cilostazol-containing medicinal product> tablets than you should, you may have signs and symptoms such as severe headache, diarrhoea, a fall in blood pressure and irregularities of your heartbeat.
Cilostazol anbefales kun til patienter, hvis symptomer ikke er blevet tilstrækkeligt bedret efter at have foretaget livsstilsændringer (så som rygestop og øget motion) og efter andre egnede foranstaltninger.
Cilostazol is only recommended for patients whose symptoms have not improved sufficiently after making life-style modifications (such as stopping smoking and increasing exercise) and after other appropriate interventions.
Plasmakoncentrationerne (målt ved AUC) for dehydro og 4`trans-hydroxy metabolitterne er 41 % og 12 % af cilostazol-koncentrationerne.
Plasma concentrations (as measured by AUC) of the dehydro and 4`-trans-hydroxy metabolites are ~41% and ~12% of cilostazol concentrations.
Dehydro metabolitten er 4-7 gange så aktiv som trombocyt antiaggregant som moderstoffet, og 4`-transhydroxy metabolitten er en femtedel så aktiv.
The dehydro metabolite is 4-7 times as active a platelet antiaggregant as the parent compound and the 4'-trans-hydroxy metabolite is one fifth as active.
• Kongestiv hjerteinsufficiens
Congestive heart failure
• Patienter med ventrikulær takykardi, ventrikulær fibrillation eller multifokal ventrikulær ektopi i anamnesen, uanset om dette er behandlet tilstrækkeligt eller ej, og patienter med forlænget QTc interval.
Patients with any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, whether or not adequately treated, and in patients with prolongation of the QTc interval
Cilostazol er en PDE III-hæmmer med antitrombocyt-aktivitet.
Cilostazol is a PDE III inhibitor with antiplatelet activity.
Forhøjet urinsyreniveau, urinstof i blodet, forhøjet blodkreatinin
Uric acid level increased, blood urea increased, blood creatinine increased
Derfor skal du kun holde op med at tage lægemidlet indeholdende cilostazol, hvis du bemærker bivirkninger, der kræver akut lægebehandling (se pkt.
Therefore, you should only stop taking <Cilostazol-containing medicinal product> if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.
En metaanalyse på basis af vægtede middelværdiforskelle på tværs af de 9 forsøg viste, at der var en signifikant, absolut samlet post-baseline forbedring på 42 m i den distance, en person maksimalt kunne gå (ACD) for cilostazol 100 mg to gange dagligt i forhold til den forbedring, der sås ved placebo.
A meta-analysis based on weighted mean differences across the nine studies indicated that there was a significant absolute overall post-baseline improvement of 42 m in maximal walking distance (ACD) for cilostazol 100 mg b.i.d.
Cilostazol er kontraindiceret til patienter med kreatinin clearance på  25 ml/min.
Cilostazol is contraindicated in patients with a creatinine clearance of  25 ml/min.
<Lægemidlet indeholdende cilostazol> er til sekundær anvendelse hos patienter, hos hvem livsstilsændringer (inklusive rygestop og [overvågede] øvelsesprogrammer) og andre passende indgreb ikke i tilstrækkelig grad har forbedret deres symptomer på claudicatio intermittens.
<Cilostazol-containing medicinal product> is for second-line use, in patients in whom lifestyle modifications (including stopping smoking and [supervised] exercise programs) and other appropriate interventions have failed to sufficiently improve their intermittent claudication symptoms.
Brug af lægemidlet indeholdende cilostazol sammen med mad og drikke Lægemidlet indeholdende cilostazol skal indtages 30 minutter før morgenmaden og aftensmåltidet.
Taking <Cilostazol-containing medicinal product> with food and drink <Cilostazol-containing medicinal product> tablets should be taken 30 minutes before breakfast and the evening meal.
Lægen skal vurdere patienten efter s3 måneders behandling med hensyn til seponering af cilostazol, hvis der observeres utilstrækkelig effekt, eller symptomerne ikke er bedret.
The physician should reassess the patient after 3 months of treatment with a view to discontinuing cilostazol where an inadequate effect is observed or symptoms have not been improved.
Forsigtighed er påkrævet ved samtidig administration af cilostrazol og ethvert andet middel, der potentielt kan nedsætte blodtrykket, på grund af muligheden for, at der kan være en ekstra hypotensiv virkning med en refleks-takykardi.
Caution is needed when co-administering cilostazol with any other agent which has the potential to reduce blood pressure due to the possibility that there may be an additive hypotensive effect with a reflex tachycardia.
Din medicin leveres i pakninger med 14, 20, 28, 30, 50, 56, 98, 100, 112 eller 168 tabletter eller som hospitalspakninger med 70 (5x14) tabletter.
Your medicine is supplied in packs of 14, 20, 28, 30, 50, 56, 98, 100, 112 or 168 tablets or hospital packs with 70 (5x14) tablets.
Patienterne skal anmodes om at indberette enhver blødningsepisode eller let opstået kontusion under behandlingen.
Patients should be warned to report any episode of bleeding or easy bruising whilst on therapy.
Udvindingen af cilostazol i modermælk kendes ikke.
The excretion of cilostazol in human milk is unknown.
Patienter, som kan være udsat for ekstra risiko for alvorlige hjertehændelser som følge af forhøjet puls, fx patienter med stabiliseret koronarsygdom, skal monitoreres nøje under behandling med cilostazol, mens brug af cilostazol hos patienter med ustabiliseret angina pectoris eller mykoardieinfarkt/koronarindgreb inden for de seneste 6 måneder eller svære takyarrytmier i anamnesen er kontraindiceret (se pkt.
Patients who may be at increased risk for serious cardiac adverse events as a result of increased heart rate, e.g. patients with stable coronary disease, should be closely monitored during treatment with cilostazol, while the use of cilostazol in patients with unstable angina pectoris, or myocardial infarction/coronary intervention within the last 6 months, or a history of severe tachyarrhythmia is contraindicated (see section 4.3).
Forsigtighed tilrådes, når cilostazol administreres sammen med CYP3A4-substrater med snævert terapeutisk indeks (f.eks. cisaprid, halofantrin, pimozid, ergot-derivater).
Caution is advised when cilostazol is co-administered with CYP3A4 substrates with a narrow therapeutic index (e.g., cisapride, halofantrine, pimozide, ergot derivates).
Hos rotter, der modtog doser under drægtighed, var fostervægten reduceret.
In rats dosed during pregnancy, foetal weights were decreased.
<Lægemidlet indeholdende cilostazol> er indiceret til forbedring af den distance, som patienter med claudicatio intermittens, der ikke har smerter i hvile, og som ikke har tegn på perifer vævsnekrose (perifer arteriesygdom Fontaine trin II) maksimalt kan gå uden smerter.
<Cilostazol-containing medicinal product> is indicated for the improvement of the maximal and painfree walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).
Patienter, der modtager behandling med cilostazol, skal fortsætte med deres livsstilsændringer (rygestop og træning) samt farmakologiske indgreb (så som lipidsænkning pg antotrombocytbehandling) for at reducere risikoen for kardiovaskulære hændelser.
Patients receiving treatment with cilostazol should continue with their life-style modifications (smoking cessation and exercise), and pharmacological interventions (such as lipid lowering and antiplatelet treatment) to reduce the risk of cardiovascular events.
Pakninger med 14, 20, 28, 30, 50, 56, 98, 100, 112 og 168 tabletter samt hospitalspakninger med 70 (5x14) tabletter i PVC/aluminium-blisterpakninger.
Cartons containing 14, 20, 28, 30, 50, 56, 98, 100, 112 and 168 tablets as well as hospital packs with 70 (5x14) tablets packed in PVC/Aluminium blisters.
Parese, hypoæstesi
Paresis, hypoaesthesia
• Den normale dosis er to 50 mg tabletter to gange dagligt (morgen og aften).
The usual dose is two 50 mg tablets twice a day (morning and evening).
På grund af cilostazols hæmmende virkning på trombocytaggregation kan der eventuelt forekomme en øget blødningsrisiko i forbindelse med operation (herunder mindre invasive indgreb som f.eks. tandudtrækning).
Due to cilostazol's platelet aggregation inhibitory effect it is possible that an increased bleeding risk occurs in combination with surgery (including minor invasive measurements like tooth extraction).
Mutagenicitetsforsøg var negative for bakteriel genmutation, bakteriel DNA-reparation, cellegenmutation hos pattedyr og kromosomaberration i in vivo knoglemarv hos mus.
Mutagenicity studies were negative in bacterial gene mutation, bacterial DNA repair, mammalian cell gene mutation and mouse in vivo bone marrow chromosomal aberrations.
• Angiotensin II-recetorblokkere (fx valsartan, candesartan)
• angiotensin II receptor blockers (e.g., valsartan, candesartan)
Efter 24 ugers behandling med cilostazol 100 mg to gange dagligt varierede stigningerne i middelværdien for ACD fra 60,4 - 129,1 meter, mens middelværdien for stigningerne i ICD varierede fra 47,3 - 93,6 meter.
increases in mean ACD ranged from 60.4 - 129.1 metres, whilst mean ICD increases ranged from 47.3 - 93.6 metres.
Du har fået ordineret lægemidlet indeholdende cilostazol for "claudicatio intermittens".
You have been prescribed <Cilostazol-containing medicinal product> for "intermittent claudication".
Kortvarig ( 4 dage) administration af ASA sammen med cilostazol tydede på en 23-25 % stigning i hæmningen af ADP-fremkaldt ex vivo trombocytaggregation sammenlignet med ASA alene.
Short term (4 days) co-administration of ASA with cilostazol suggested a 23-25% increase in inhibition of ADP-induced ex vivo platelet aggregation when compared to ASA alone.
• Den normale dosis er én 100 mg tablet to gange dagligt (morgen og aften).
The usual dose is one 100 mg tablet twice a day (morning and evening).
Der skal udvises forsigtighed ved ordinering af cilostazol til patienter med atrie- eller ventrikelektopi og patienter med atrieflimren eller -flagren.
Caution should be exercised when prescribing cilostazol for patients with atrial or ventricular ectopy and patients with atrial fibrillation or flutter.
Visse typer medicin kan gribe forstyrrende ind i virkningen af lægemidlet indeholdende cilostazol, hvis de tages samtidig.
Certain medicines may interfere with the effect of <Cilostazol-containing medicinal product> when taken together.
De primære isoenzymer, der er involveret i metabolismen, er cytokrom P-450 CYP3A4, i mindre omfang CYP2C19 og i endnu mindre grad CYP1A2.
The primary isoenzymes involved in its metabolism are cytochrome P-450 CYP3A4, to a lesser extent, CYP2C19, and to an even lesser extent CYP1A2.
hvis du tager både acetylsalicylsyre og clopidogrel eller en anden kombination af to eller flere lægemidler, der kan øge din risiko for blødninger [spøg din læge eller apotekspersonalet, hvis du er usikker]
if you are taking both acetylsalicylic acid and clopidogrel, or any combination of two or more medicines which can increase your risk of bleeding [ask your doctor or pharmacist if you are not sure] if you have severe kidney disease or moderate or severe liver disease.
4`-trans-hydroxy-metabolitten med en styrke på en femtedel af cilostazols, dannes tilsyneladende primært via CYP2C19.
The 4`-trans-hydroxy metabolite, with potency one-fifth that of cilostazol, appears to be formed primarily via CYP2C19.
Pyreksi,smerter
Pyrexia, pain
• Calciumkanalblokkere (fx verapamikl, amlodipin)
• calcium channel blockers (e.g., verapamil, amlodipine)
Derfor øger lægemidler, der hæmmer CYP3A4 (f.eks. nogle makrolider, azole svampemidler, proteasehæmmere) eller CYP2C19 (som protonpumpehæmmere, PPI), den samlede farmakologiske aktivitet og kan potentielt forøge de uønskede virkninger af cilosatzol.
Therefore, drugs inhibiting CYP3A4 (e.g., some macrolides, azole antifungals, protease inhibitors) or CYP2C19 (like proton pump inhibitors, PPIs) increase the total pharmacological activity and could have the potential to enhance the undesirable effects of cilostazol.
Cilostazol hæmmer desuden formeringen af bløde muskelceller hos rotter og humane bløde muskelceller in vitro og hæmmer reaktionen med frigivelse af trombocytter for trombocytafledt vækstfaktor og PF-4 i humane trombocytter.
Cilostazol also inhibits smooth muscle cell proliferation in rat and human smooth muscle cells in vitro, and inhibits the platelet release reaction of platelet-derived growth factor and PF-4 in human platelets.
Virkningen af CYP3A4- og CYP2C19-inducere (f.eks. carbamazepin, fenytoin, rifampicin og perikum) på cilostazols farmakokinetik er ikke vurderet.
The effect of CYP3A4 and CYP2C19 inducers (such as carbamazepine, phenytoin, rifampicin and St. John's wort) on cilostazol pharmacokinetics has not been evaluated.
Da cilostazol i høj grad metaboliseres ved hjælp af leverenzymer, er det kontraindiceret til patienter med moderat eller svær leverinsufficiens.
Since cilostazol is extensively metabolised by hepatic enzymes, it is contraindicated in patients with moderate or severe hepatic impairment.
• Antikoagulanter (fx warfarib, dabigatran, rivaroxaban, apixaban eller hepariner med lav molekylvægt).
• anticoagulant medicines (e.g. warfarin, dabigatran, rivaroxaban, apixaban or low molecular weight heparins).
Det er påvist, at cilostazol øger AUC for lovastatin (følstomt substrat for CYP3A4) og dets -hydroxysyre med 70 %.
Cilostazol has been shown to increase the AUC of lovastatin (sensitive substrate for CYP3A4) and its hydroxy acid by 70%.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP Blisterbakker
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {Blister}
Hvis du føler dig svimmel, når du har taget tabletter indeholdende cilostazol, må du IKKE køre bil og ikke anvende værktøj eller maskiner.
If you feel dizzy after taking <Cilostazol-containing medicinal product> tablets, DO NOT drive and do not use any tools or machines and inform your doctor or pharmacist.
På basis af data fra 9 placebokontrollerede forsøg (hvor 1.634 patienter blev eksponeret for cilostazol) er det påvist, at cilostazol forbedrer motionskapaciteten vurderet efter ændring i Absolute Claudication Distance
From data generated in nine placebo-controlled studies (where 1,634 patients were exposed to cilostazol), it has been demonstrated that cilostazol improves exercise capacity as judged by changes in Absolute Claudication Distance (ACD, or maximal walking distance) and Initial Claudication Distance (ICD, or pain-free walking distance) upon treadmill testing.
Egnetheden af behandlingen med cilostazol sdkal nøje overvejes i forhold til andre behandlingsmuligheder, som fx revaskularisering.
The suitability of treatment with cilostazol should be carefully considered alongside other treatment options such as revascularisation.
Ikke almindelige Søvnløshed, unormale drømme Ukendte
Insomnia, abnormal dreams
• Aktivt stof: cilostazol.
The active substance is cilostazol.
Cilostazpæ skal initieres af læger, der har erfaring i behandling af claudicatio intermittens (se ogs¨pkt.
Cilostazol should be initiated by physicians experienced in the management of intermittent claudication (see also section 4.4).
og AUC for 4`-transhydroxy-cilostazol var 173 % og 209 % større hos forsøgsdeltagere med svær nyreinsufficiens.
The Cmax and AUC of 4'-transhydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment.
Palpitation, takykardi, angina pectoris, arytmi, ventrikulære ekstrasystoler
Palpitation, tachycardia, angina pectoris, arrhythmia, ventricular extrasystoles
I kliniske forsøg reducerede rygning (der fremkalder CYP1A2) plasmakoncentrationerne af cilostazol med
In clinical trials, smoking (which induces CYP1A2) decreased cilostazol plasma concentrations by 18%.
Under behandling med <Lægemidltr indeholdende cilostazol> skal du sørge for,
During treatment with <Cilostazol-containing medicinal product> make sure that
Eksem, hududslæt, Stevens-Johnson syndrom, toksisk epidermal nekrolyse, urticaria
Eczema, skin eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
Der har været sjældne eller meget sjældne rapporter om hæmatologisk unormale forhold, herunder trombocytopæni, leukopeni, agranulocytose, pancytopeni og aplastisk anæmi (se pkt.
There have been rare or very rare reports of haematological abnormalities including thrombocytopenia, leucopenia, agranulocytosis, pancytopenia and aplastic anaemia (see section 4.8).
6.2 Uforligneligheder
6.2 Incompatibilities
Cilostazol metaboliseres i høj grad af CYP-enzymer, især CYP3A4 og CYP2C19 og i mindre omfang CYP1A2.
Cilostazol is extensively metabolised by CYP enzymes, particularly CYP3A4 and CYP2C19 and to a lesser extent CYP1A2.
Dersom patienter fik stærke hæmmere af CYP3A4 eller CYP2C19, viste plasmaniveauerne af cilostazol sig at blive forøget.
In the case of patients receiving strong inhibitors for CYP3A4 or CYP2C19, plasma levels of cilostazol were shown to be increased.
I sådanne tilfælde anbefales en cilostazol-dosis på 50 mg to gange daglig (se pkt.
In such cases, a cilostazol dosage of 50 mg twice daily is recommended (see section 4.5 for further information).
Hepatitis, unormal leverfunktion, gulsot
Hepatitis, hepatic function abnormal, jaundice
De fleste patienter kom sig efter seponering af cilostazol.
Most patients recovered on discontinuation of cilostazol.
Dehydro-metabolitten, der er 4-7 gange kraftigere end cilostazol til hæmning af trombocytaggregation, dannes tilsyneladende primært via CYP3A4.
The dehydro metabolite, which has 4-7 times the potency of cilostazol in inhibiting platelet aggregation, appears to be formed primarily via CYP3A4.
Ikke almindelige Myokardieinfarkt, atriefibrillering, kongestiv hjerteinsufficiens, supraventrikulær takykardi, ventrikulær takykardi, synkope
Myocardial infarction, atrial fibrillation, congestive heart failure, supraventricular tachycardia, ventricular tachycardia, syncope
• Diuretika (vanddrivende midler - fx hydrochlorothiazid, furosemid)
• Diuretics (e.g., hydrochlorothiazide, furosemide)
og AUC for dehydro-metabolitten var henholdsvis 41 % og 47 % lavere hos forsøgsdeltagere med svær nyreinsufficiens sammenlignet med forsøgsdeltagere med normal nyrefunktion.
The Cmax and AUC of the dehydro metabolite were 41% and 47% lower respectively in the severely renally impaired subjects compared to subjects with normal renal function.
Cilostatol-behandling er kontraindiceret hos patienter, der modtager to eller flere yderligere antitrombocyt-/antikoagulant-behandlinger (se pkt.
Cilostazol treatment is contraindicated in patients receiving two or more additional antiplatelet/anticoagulant agents (see section 4.3).
Følgende bivirkninger er indberettet for lægemidlet indeholdende cilostazol.
The following side effects have been reported for <Cilostazol-containing medicinal product>.
Er du i tvivl, så spørg lægen eller på apoteket.
If you have any further questions, please ask your doctor or your pharmacist.
Reduktion af dosis til 50 mg daglig anbefales hos patienter, der får lægemidler med stærk CYP3A4hæmning, fx visse macrolider, azol-fungicider, proteasehæmmere eller lægemidler, som stærkt hæmmer CYP2C19, fx omeprazol (se pkt.
Reduction of the dose to 50 mg twice daily is recommended in patients receiving medicines that strongly inhibit CYP3A4, for example some macrolides, azole antifungals, protease inhibitors, or medicines that strongly inhibit CYP2C19, for example omeprazole (see sections 4.4 and 4.5).
• Betablokkere (fx labetalol, carvedilol);
• beta blockers (e.g., labetalol, carvedilol);
Ved lavere dosisniveauer blev der observeret hæmning af knogledannelsen.
At lower dose levels, retardations of ossification were observed.
Meget almindelige bivirkninger (mere end 1 af 10 mennesker)
Very common side effects (affecting more than 1 in 10 people) headache abnormal stools diarrhoea
• hvis du er allergisk (overfølsom) over for cilostazol eller et af de øvrige indholdsstoffer i lægemidlet indeholdende cilostazol.
Do not take <Cilostazol-containing medicinal product> if you are allergic (hypersensitive) to cilostazol or any of the other ingredients of <Cilostazolcontaining medicinal product>.
[Se Bilag I - Udarbejdes nationalt]
[See Annex I - To be completed nationally]
Cytochrom P-450 enzymsubstrater
Cytochrome P-450 enzyme substrates
• De øvrige ingredienser er majsstivelse, mikrokrystallinsk cellulose, carmellosecalcium, hypromellose og magnesiumstearat.
The other ingredients are maize starch, microcrystalline cellulose, carmellose calcium, hypromellose and magnesium stearate.
• Tag altid lægemidlet indeholdende cilostazol nøjagtigt efter lægens anvisning.
Always take <Cilostazol-containing medicinal product> exactly as your doctor has told you.
Forlænget blødningstid, trombocytæmi
Bleeding time prolonged, thrombocythaemia
Blødningstendens, trombocytopeni, granulocytopeni, agranulocytosis, leukopeni, pancytopeni, aplastisk anæmi
Bleeding tendency, thrombocytopenia, granulocytopenia, agranulocytosis, leukopenia, pancytopenia, aplastic anaemia
• ACE-hæmmere (fx captopril, lisinopril)
• ACE inhibitors (e.g., captopril, lisinopril)
Blod og llymfesystem Almindelige
Blood and the lymphatic system disorders
Meget almindelige Diare, unormal afføring Almindelige
Very common Diarrhoea, abnormal faeces Common